Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

454 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis.
Isobe T, Naiki T, Sugiyama Y, Naiki-Ito A, Nagai T, Etani T, Nozaki S, Iida K, Noda Y, Shimizu N, Tomiyama N, Banno R, Kubota H, Hamamoto S, Ando R, Kawai N, Yasui T. Isobe T, et al. Among authors: tomiyama n. Int J Clin Oncol. 2022 Jan;27(1):165-174. doi: 10.1007/s10147-021-02046-z. Epub 2021 Oct 11. Int J Clin Oncol. 2022. PMID: 34633579
Efficacy of fosfomycin in preventing infection after endoscopic combined intrarenal surgery in periods of limited supply of first- and second-generation cephalosporins.
Etani T, Asaoka M, Kondo S, Wachino C, Tomiyama N, Hattori T, Nagai T, Iida K, Taguchi K, Naiki T, Hamamoto S, Okada A, Kawai N, Yanagita T, Nakamura A, Yasui T. Etani T, et al. Among authors: tomiyama n. Int J Urol. 2022 Sep;29(9):977-982. doi: 10.1111/iju.14896. Epub 2022 Apr 5. Int J Urol. 2022. PMID: 35384075
Clinical characteristics of Raoultella ornithinolytica bacteremia and antimicrobial susceptibility of Raoultellaornithinolytica.
Etani T, Kondo S, Yanase T, Morikawa T, Aoki M, Gonda M, Tomiyama N, Nagai T, Iida K, Iwatsuki S, Taguchi K, Naiki T, Hamamoto S, Okada A, Kawai N, Nakamura A, Yasui T. Etani T, et al. Among authors: tomiyama n. J Infect Chemother. 2023 May;29(5):554-557. doi: 10.1016/j.jiac.2023.01.023. Epub 2023 Feb 3. J Infect Chemother. 2023. PMID: 36738858
Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinoma.
Tomiyama N, Tasaki Y, Hamamoto S, Sugiyama Y, Naiki T, Etani T, Taguchi K, Matsuyama N, Sue Y, Mimura Y, Odagiri K, Noda Y, Aoki M, Moritoki Y, Nozaki S, Kurokawa S, Okada A, Kawai N, Furukawa-Hibi Y, Yasui T. Tomiyama N, et al. Int J Urol. 2023 Sep;30(9):754-761. doi: 10.1111/iju.15198. Epub 2023 May 7. Int J Urol. 2023. PMID: 37150513
Elevated eosinophils proportion as predictor of immune-related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma.
Tasaki Y, Hamamoto S, Sugiyama Y, Tomiyama N, Naiki T, Etani T, Taguchi K, Matsuyama N, Sue Y, Mimura Y, Kubota H, Noda Y, Aoki M, Moritoki Y, Nozaki S, Kurokawa S, Okada A, Kawai N, Yasui T, Kimura K. Tasaki Y, et al. Among authors: tomiyama n. Int J Urol. 2023 Oct;30(10):866-874. doi: 10.1111/iju.15220. Epub 2023 Jun 6. Int J Urol. 2023. PMID: 37278575
454 results